SHS’s investing in Swiss life science company evitria AG

The SHS V fund managed by Tübingen-based SHS Gesellschaft für Beteiligungsmanagement has acquired a joint stake in Swiss evitria AG together with AFINUM. The life science company supplies large pharmaceutical and biotech companies with customized antibodies for research purposes.

SHS Gesellschaft für Beteiligungsmanagement is based in Tübingen, Germany and invests in medical technology and life science companies with a focus on expansion financing, changes in shareholder structures and successor situations. It was founded in 1993 and has since then gained extensive experience as an industry investor, which supports the growth of its portfolio companies through a network of partnerships, regulatory issues or entering new markets.

Walder Wyss has advised SHS as legal advisor in this transaction. The team included Robert von Rosen (Partner, Corporate/M&A, in picture), Alexander Gutmans (Partner, Corporate/Venture Capital), Martin Busenhart (Partner, Tax) and Luciano Schmid (Associate, Tax).

Involved fees earner: Martin Busenhart – Walder Wyss Ltd.; Alexander Gutmans – Walder Wyss Ltd.; Luciano Schmid – Walder Wyss Ltd.; Robert von Rosen – Walder Wyss Ltd.;

Law Firms: Walder Wyss Ltd.;

Clients: SHS;

Print Friendly, PDF & Email